Article Details

Interim data from phase III study presented at ASH 2022 show Hemlibra achieved ...

Retrieved on: 2022-12-11 12:18:04

Tags for this article:

Click the tags to see associated articles and topics

Interim data from phase III study presented at ASH 2022 show Hemlibra achieved .... View article details on HISWAI: https://www.marketscreener.com/quote/stock/CHUGAI-PHARMACEUTICAL-CO-6491165/news/Interim-data-from-phase-III-study-presented-at-ASH-2022-show-Hemlibra-achieved-meaningful-bleed-cont-42522784/

Excerpt

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced interim results from the phase III HAVEN 7 study. · American Society of Hematology ...

Article found on: www.marketscreener.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up